Fresh Off $30M Round, Seattle Startup Lumen Bioscience Adds Microsoft Vet Jeff Raikes to Board

Seattle-based biotech startup Lumen Bioscience raised a $30M Series C extension and announced several leadership updates. WestRiver Group led the latest funding round, bringing the company’s total capital raised to $186.8M. The new investment will help Lumen accelerate its pipeline of orally delivered biologic drugs made from genetically engineered spirulina, a type of blue-green algae.